Generic drug report attacks brand-name industry

Guest Contributor
November 11, 2013

The Canadian Generic Pharmaceutical Association (CGPA) has released a report detailing what it calls the failure of brand-name drug companies to spend at least 10% of Canadian revenues on R&D. The report draws its information from the latest report of the Patented Medicines Prices Review Board. It shows that members of Canada's Research-Based Pharmaceutical Companies (Rx&D) spent 6.6% of revenues in 2012 with outlays on basic research dropping 30.5% between 2011 and 2012....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.